Stevenage, UK, January 7 2013 – Stevenage Bioscience Catalyst (SBC), the UK’s first open innovation (OI) bioscience campus, will be debating the role of OI across the biotech and medtech sectors at the prestigious Biotech Showcase 2013 in San Francisco. In the workshop on January 9, 'Open Innovation: Driver of Future Healthcare Solutions?', CEO Martino Picardo will be joined by speakers from the venture capital and pharmaceutical industries. The panel, chaired by David Flores, President and CEO of Biocentury, is expected to cover issues such as how to use OI to tackle difficult research questions, as well as how to protect competitiveness and keep venture capital funders on board. Crowdfunding, the area of expertise for panellist Poliwogg Inc, and the latest OI initiatives will also be discussed. Other participants include GlaxoSmithKline, Syncona Partners (recently launched with £200m of initial capital from the Wellcome Trust), and PureTech Ventures. Biotech Showcase 2013 is an investor and partnering conference running from January 7-9 in parallel with the JP Morgan Healthcare Conference in San Francisco. It is expected to feature over 230 presentations, with in excess of 1500 attendees.
View Press ReleaseCopyright © 2023 Stevenage Bioscience Catalyst
We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.